NCT05201027终止不适用
A Prospective, Non-comparative, Multicenter Trial to Optimize the IOL Constant of a New Multifocal IOL
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- Optimization of the IOL constant
研究概览
简要总结
Prospective, non-comparative, multicenter study on medical device with 6 months follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patient of any gender;
- •Patient with clinically significant bilateral age-related cataracts with planned phacoemulsification cataract extraction and suitable for implantation of a posterior chamber trifocal intraocular lens as determined by investigator's medical judgement;
- •Projected postoperative corrected distance visual acuity (CDVA) better than 0.2 LogMAR as determined by investigator's medical judgement;
- •Preoperative keratometric (corneal) astigmatism ≤1.5 D;
- •Clear intraocular media other than cataract;
- •Requiring an IOL power within the available range of the investigational IOL (15.0 to +27.0 D, in 0.5 D increments);
- •Patient agrees to have surgery of the second eye performed between 1 day and 10 days after the surgery of the first eye.
- •Given written informed consent by patient;
- •Patient willing and able to comply with examination procedures and schedule for follow-up visits;
排除标准
- •Presence of uncontrolled systemic disease that could increase the operative risk or confound the outcome including but not limited to diabetes mellitus, active cancer treatment, mental illness, dementia, immunocompromised, connective tissue disease, clinically significant atopic disease, etc.;
- •Ocular condition that may predispose patient to future complications, per investigator's medical judgement, including but not limited to severe dry eye, anterior segment pathology, glaucoma (uncontrolled despite intake of medication), macular degeneration;
- •Clinically significant corneal abnormalities, including corneal dystrophy (epithelial, stromal or endothelial dystrophy), irregularity, inflammation or oedema as per Investigator's medical judgement; conditions including but not limited to keratitis, keratoconjunctivitis, kerato uveitis, keratopathy, keratectasia;
- •Previous intraocular or corneal/refractive surgery that might confound the outcome of the investigation or increase the risk to the patient (including corneal transplants, removal of pterygium etc.);
- •Use of and foreseeable use of systemic medications that may confound the outcome or increase the risk to the patient per investigator's medical judgement (e.g., steroids, Tamsulosin Hydrochloride or other medications including anticholinergics or alpha-adrenergic blocking agents with similar side effects [e.g. small pupil/floppy iris syndrome], anti-metabolites, etc.);
- •Patients with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders, optic nerve atrophy etc.) or any other pathologies of the eye that are predicted to cause future acuity loss to 0.2 LogMAR (CDVA) or worse;
- •Patients with conditions that increase the risk of zonular rupture during cataract extraction procedure that may affect the postoperative centration or tilt of the lens;
- •Patients with previous refractive surgery procedures, including but not limited to LASIK, limbal relaxing incision;
- •Planned concomitant ocular procedure during cataract surgery or within the next 6 months (e.g. glaucoma surgery including implantation of MIGS, astigmatic correction surgery, penetrating keratoplasty, laser-assisted in situ keratomileusis);
- •Patients who are expected to require retinal laser treatment within the next 6 months per investigator's medical judgement;
- •Amblyopia;
- •Rubella, congenital, traumatic or complicated cataracts;
- •History of or current anterior or posterior segment inflammation, including but not limited to iritis or uveitis;
- •Microphthalmos or macrophthalmos;
- •Iris defects (e.g. aniridia);
- •Optic nerve atrophy;
- •Pseudoexfoliation;
- •Keratoconus or irregular astigmatism;
- •Inability to measure keratometry or biometry (including but not limited to cataract density, patient unable to focus for longer time etc.);
- •Pathologic miosis;
- •Pregnant, lactating during the course of the investigation, or another condition with associated fluctuation of hormones that could lead to refractive changes;
- •Patient whose freedom is impaired by administrative or legal order;
- •Concurrent participation in another drug or device investigation that could confound the outcome of this investigation.
研究组 & 干预措施
trifocal intraocular lens
Experimental
Implantation of new trifocal intraocular lens
干预措施: trifocal intraocular lens (Device)
结局指标
主要结局
Optimization of the IOL constant
时间窗: 6 months
Optimization of the calculated IOL constant with regression analysis by utilizing the following data measured during the study: Corneal radii, axial length, anterior chamber depth, IOL power, target refraction, manifest refraction and refraction distance
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Study to Confirm Safety and Performance of a New Multifocal IOLCataract SenileNCT06247683Carl Zeiss Meditec AG135
已完成
不适用
HAART Model 300 Annuloplasty RingAortic RegurgitationNCT01400841Biostable Science & Engineering18
已完成
不适用
STARflo European Safety and Efficacy StudyOpen Angle GlaucomaNCT02272569iSTAR Medical42
已完成
不适用
BIOLUX P-IV CHINA ( BIOTRONIK )Peripheral Arterial DiseaseNCT02912715Biotronik (Beijing) Medical Device Ltd.158
已完成
不适用
Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis SubjectsMSMultiple SclerosisNCT01128075Merck KGaA, Darmstadt, Germany198